Clear Search

Showing 3 results for “Claudepierre P”.

January 2024

Influence of Sex on the Persistence of Different Classes of Targeted Therapies for Psoriatic Arthritis: A Cohort Study of 14 778 Patients from the French Health Insurance Database (SNDS)

RMD Open. 2023;9(4):e003570 doi: 10.1136/rmdopen-2023-003570

Nationwide study involving 14 778 new users of targeted therapies with PsA found treatment persistence to be lower for women than men for TNFi and IL17i but not for IL-12/23i, IL-23i or JAK inhibition.

more…

April 2023

Factors Associated with the Retention of Secukinumab in Patients with Axial Spondyloarthritis in Real-world Practice: Results from a Retrospective Study (FORSYA)

RMD Open 2023;9:e002802 doi: 10.1136/rmdopen-2022-002802

This study reported the overall retention of secukinumab in daily practice in the period following its approval in France was approximately 59% at 1 year in axSpA patients. The aim of this study was to determine whether OSI were predictive of secukinumab retention at 1 year.

more…

May 2022

Risk of major adverse cardiovascular events in patients initiating biologics/apremilast for psoriatic arthritis: a nationwide cohort study

doi: 10.1093/rheumatology/keab522

Pina Vegas and her colleagues sought to assess the relative risk of MACEs in patients with PsA initiating bDMARDs or apremilast. They found that overall, the data produced overall a positive picture regarding the incidence of MACE in treatment.

more…